Jennifer E Amengual
SWOG Cancer Research Network · Yale University Cancer Center LAO · Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jennifer E Amengual as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05890352 · Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentSWOG Cancer Research Network · recruiting · Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements · principal investigator
- Ph1NCT05627245 · Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentNational Cancer Institute (NCI) · active not recruiting · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma · principal investigator
- Ph2NCT04750941 · Study of Copanlisib and Ketogenic DietColumbia University · terminated · Follicular Lymphoma, Endometrial Cancer · principal investigator
- Ph3NCT03355768 · Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLJennifer Amengual · withdrawn · Lymphoma, T-Cell, Peripheral · principal investigator
- Ph1/Ph2NCT02091063 · ACY-1215 for Relapsed/Refractory Lymphoid MalignanciesJennifer Amengual · terminated · Lymphoma, Lymphoid Malignancies · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Columbia University NCI Community Oncology Research ProgramUG1CA189960 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2022 to 2026 · $1,049,702 awarded in 2026Same name and institution; not confirmed by an ID
- Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphomaR01CA222931 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2018 to 2022 · $370,575 awarded in 2022Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT05890352
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT05627245
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:24 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 110 citationsRCR 3.9
- 107 citationsRCR 3.5
- Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.Lancet Oncol · 201897 citationsRCR 3.4
- Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.J Clin Oncol · 202194 citationsRCR 4.7
- 65 citationsRCR 2.1
- 54 citationsRCR 1.4
- Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.Br J Haematol · 201933 citationsRCR 1.9
- 8 citationsRCR 0.8
- 5 citationsRCR 2.5